AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02286388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).
Description: Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds.
Study NCT02286388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).
Description: Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds.
Study NCT02286388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)
Description: Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
Study NCT02286388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)
Description: Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
Study NCT02548065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balneotherapy
Description: Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs
Study NCT02548065 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bath with Thermal tap water
Study NCT02415790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
Study NCT02415790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027 matching placebo
Description: E2027 matching placebo capsule will be administered.
Study NCT03939234 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PD-L1, PD-L2 peptides with Montanide ISA51
Description: PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
Study NCT01019564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete Easy Rub Formula MPS
Description: Multi-purpose solution
Study NCT01019564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquify MPS
Description: Multi-purpose solution
Study NCT04401657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve with adenosine stress testing
Description: ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
Study NCT01644253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 10-20 mg/kg + bendamustine
Description: TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
Study NCT02296411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259 12.5 µg
Description: comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
Study NCT02296411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF 5259 placebo
Description: comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
Study NCT02476487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG PET CT
Description: FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal.
Study NCT02649634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
Study NCT02649634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
Study NCT04471896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Joovv Mini
Description: Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.
Study NCT01136395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 4 weeks before ABOi LD transplantation
Study NCT01136395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: living donor transplantation
Description: living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
Study NCT01136395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deceased donor transplantation
Description: deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
Study NCT03931174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Addiction Technology Transfer Center (ATTC) Training Strategy
Description: Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
Study NCT03931174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy
Description: Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
Study NCT00607048 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel + Carboplatin + CP-870,893
Description: Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
Study NCT00607048 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel + Carboplatin + CP-870,893
Description: Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
Study NCT03978273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Night-time brace + virtual-brace
Description: Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~* They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~* They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180.
Study NCT03978273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Night-time brace only
Description: Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180.
Study NCT00928330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose
Study NCT00928330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous repeating dose
Study NCT00928330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab-MCC-DM1
Description: Intravenous repeating dose
Study NCT04267640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG0001
Description: AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly
Study NCT04267640 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00238264 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
Study NCT01560351 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
Study NCT01560351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
Study NCT05229939 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Study NCT02419027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GI Flora
Study NCT02419027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00002586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid
Study NCT00002586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocopherol
Study NCT02575430 — intervention group
Intervention type: OTHER
Intervention: No treatment: retrospective chart review
Study NCT00165009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolution clip (endo-clipping device)
Description: Resolution clip (endo-clipping device)
Study NCT02644408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol（Yining）
Description: Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
Study NCT02644408 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
Study NCT02644408 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
Study NCT02644408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
Study NCT02644408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
Study NCT03867630 — intervention group
Intervention type: PROCEDURE
Intervention: Transforaminal Block
Description: Epidural block via neural foramen of lumbar spine
Study NCT02351232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT02351232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00018902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Standard anti-depressant treatment with the SSRI fluoxetine
Study NCT00018902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Standard antidepressant treatment with the non-SSRI medication venlafaxine
Study NCT00018902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT addresses maladaptive beliefs in order to encourage behavioral change
Study NCT00018902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Standard anti-depressant treatment with the SSRI fluoxetine
Study NCT03215784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Study NCT03215784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Study NCT03215784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01221857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiCord®
Description: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
Study NCT02562547 — intervention group
Intervention type: DEVICE
Intervention: Hem-Avert Perianal Stabilizer
Description: The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
Study NCT01291121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal expansile gas and ranibizumab injection
Description: Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
Study NCT01802086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emla-cream
Description: Topical anaesthetic
Study NCT01802086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Miniderm cream
Description: Topical
Study NCT04405219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain
Description: Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
Study NCT04405219 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain
Description: Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
Study NCT03078062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
Study NCT03078062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administration of a single-dose of Normal saline during spinal anesthesia
Study NCT00380562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience Corps
Description: High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
Study NCT04097548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Description: Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
Study NCT01110187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: 200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
Study NCT04121286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.
Study NCT01982981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water provision
Description: perception behavioral change at the beginning and at the end of the intervention
Study NCT01110187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin
Description: 20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
Study NCT01838044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin and celecoxib
Description: During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
Study NCT01838044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo and celecoxib
Description: Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
Study NCT01982981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water provision
Description: After participants are recruited, drink 2L of water for 8 weeks.
Study NCT01540760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCAF5352A
Description: Multiple ascending doses
Study NCT04675047 — intervention group
Intervention type: OTHER
Intervention: no intervention for healthy control
Description: observational study - no intervention
Study NCT01540760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching MCAF5352A, multiple doses